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Three classes of compounds were chosen for investigation to find a high affinity and 
selective iodinated peripheral benzodiazepine receptor (PBR) ligand; indol-3-
ylglyoxylamides, pyrazolopyrimidines, and pyridopyrrolooxazepines and 
pyrrolobenzoxazepines. These compounds were chosen from a literature search for their 
high PBR affinity and selectivity, ease of synthesis, and the potential for 
radioiodination. 
 
Fifteen new halogenated N,N-dialkylindol-3-ylglyoxylamides were synthesised and 
tested for their PBR and central benzodiazepine receptor (CBR) affinity. The 
compounds IC50 values for the PBR ranged from 7.8 – 618 nM, and a structure activity 
relationship (SAR) was determined. Brominated compounds had higher binding 
affinities than their iodinated analogues, and indoles with a chloro substituent on 
position 5 had higher binding affinities than the non-chlorinated compounds. The 
optimum alkyl chain length was found to be two carbons. The highest affinity iodinated 
ligand, with a PBR IC50 of 8.2 nM, was radiolabelled with 123I in 55-60% radiochemical 
yield and evaluated in vivo in Sprague-Dawley rats. Biodistribution studies revealed 
high uptake of the radiotracer in organs known to contain PBR, such as the kidneys, 
adrenals, heart, liver and lungs. Drug competition studies showed that the PBR drugs 
PK11195 and Ro5-4864, when injected into the rat 5 min prior to injection of the 
radiotracer, significantly decreased uptake of radiotracer into those organs. The CBR 
drug, flumazenil, did not decrease the uptake of the radiotracer. Metabolite studies 
showed that the radiotracer was > 95% intact in the heart, kidneys, adrenals, and brain 
after 3 h and was 65% intact in the plasma. This compound is the first radiolabelled 
 x 
PBR ligand of this class, and is an excellent candidate for future studies and may lead to 
a clinically useful imaging agent. 
 
Three pyrazolopyrimidines were synthesised, with lengths of the alkyl chains being 
methyl, ethyl, or propyl groups. The highest affinity ligand, with the propyl groups, 
displayed an IC50 of 7.9 nM, however, only the compound with ethyl groups displaying 
an IC50 of 11.7 nM was radiolabelled with 123I in 95% radiochemical yield, and 
evaluated in vivo in rats. This compound showed high uptake into organs known to 
contain PBR, and also showed an interesting result in which pre-administration of Ro5-
4864 did not cause any significant decrease of uptake of radiotracer in the kidney or 
heart, however PK11195 did cause of significant decrease in these organs. This 
compound provides the first radioiodinated PBR ligand of this class. 
 
Two pyrrolopyridooxazepines and two pyrrolobenzoxazepines were synthesised and 
tested. One of the compounds was found to be inactive, while the others had moderate 
PBR IC50 values of 24-39 nM. The moderate binding affinity for these compounds 














List of Abbreviations iv 
Publications/Presentations vii 
Abstract ix 
Table of Contents xi 
List of Figures xvii 
List of Schemes xxi 
List of Tables xxiii 
1 Introduction 1 
1.1 Peripheral Benzodiazepine Receptors 1 
1.2 Molecular Structure of the PBR 2 
1.3 Cellular and Tissue Location of the PBR 4 
1.4 Endogenous Ligands for the PBR 5 
1.5 Synthetic PBR Ligands 7 
1.6 Possible Functions of the PBR 9 
1.6.1 Cellular Respiration 9 
1.6.2 Steroid and Bile Acid Biosynthesis 9 
1.6.3 Modulation of Apoptosis 12 
1.6.4 Cellular Proliferation and Differentiation 12 
1.6.5 Immune Responses 13 
1.7 The PBR under Pathological Conditions 14 
1.7.1 Neurodegenerative Disorders 14 
 xii
1.7.2 Inflammation and Autoimmune Diseases 15 
1.7.3 Cancer 16 
1.8 Peripheral Benzodiazepine Receptor Ligands 17 
1.8.1 Benzodiazepines 17 
1.8.2 Isoquinoline Carboxamides 18 
1.8.3 Imidazopyridines and Imidazopyridazines 18 
1.8.4 Pyrazolopyrimidines 20 
1.8.5 Pyrrolobenzothiazepines, pyrrolobenzoxazepines and 
pyridopyrrolooxazepines 21 
1.9 Radiopharmaceutical Chemistry 26 
1.9.1 Radionuclides 26 
1.9.2 Radiopharmaceuticals 27 
1.9.3 Radiation Detection 28 
1.10 Radiolabelled PBR Ligands 31 
1.10.1 Iodine-123 Radiolabelled PBR Ligands 33 
1.11 Project Aims 34 
2 Synthesis of N,N-Dialkyl-2-phenylindol-3-yl-glyoxylamides 36 
2.1 N,N-Dialkyl-2-phenylindol-3-ylglyoxylamides for the PBR 36 
2.2 Target Compounds 37 
2.3 General Synthetic Strategy 39 
2.4 Synthesis of 5-Chloroindol-3-ylglyoxylamide Analogues 40 
2.4.1 Synthesis of Glyoxylyl Chloride Intermediates 40 
2.4.2 Synthesis of N,N-Dialkyl-[5-chloro-2-(4-halophenyl)-indol-3-yl]-
glyoxylamides 41 
2.5 Synthesis of Indol-3-ylglyoxylamide Analogues 45 
 xiii
2.5.1 Synthesis of Glyoxylyl Chloride Intermediates 45 
2.5.2 Amination of [2-(4-Halophenyl)indol-3-yl]glyoxylyl Chlorides 48 
2.6 Synthesis of meta-Substituted Indol-3-ylglyoxylamide Analogues 49 
2.7 Synthesis of 2-(4-Fluorophenyl)indol-3-ylglyoxylamide Analogue 52 
2.8 In Vitro Binding of N,N-Dialkyl-2-phenylindol-3-ylglyoxylamides 54 
2.9 Lipophilicity Estimations 57 
2.10 Comparison with Similar New Indolylglyoxylamides 58 
2.11 Conclusion 60 
3 Synthesis of 2-Arylpyrazolo[1,5-a]-pyrimidin-3-yl Acetamides 61 
3.1 2-Arylpyrazolo[1,5-a]pyrimidin-3-yl Acetamides 61 
3.2 Rationale 64 
3.3 General Synthetic Strategy 64 
3.4 Synthesis of 4-Iodobenzoylacetonitrile Intermediate 66 
3.5 Synthesis of Iodinated N,N-Dialkylbutanamides 67 
3.6 Synthesis of 3-Aminopyrazoles 70 
3.7 Synthesis of Pyrazolopyrimidines 71 
3.8 In Vitro Binding of 2-Arylpyrazolo[1,5-a]pyrimidin-3-yl Acetamides 73 
3.9 Conclusions and Future Directions 74 
4 Synthesis of Pyridopyrrolooxazepines and Pyrrolobenzoxazepines 77 
4.1 Pyrrolobenzothiazepines for the PBR 77 
4.2 Pyridopyrrolo and Pyrrolobenzoxazepine Ligands for PBR 77 
4.3 Rationale 79 
4.4 General Synthetic Scheme 79 
4.5 Synthesis of Ethyl (±)-α-Bromoarylacetates 81 
4.6 Synthesis of Pyridopyrrolooxazepines 81 
 xiv
4.7 Synthesis of Pyrrolobenzoxazepines 87 
4.8 Synthesis of 4-Halogenated Pyrrolobenzoxazepines 90 
4.9 In Vitro Binding of Pyridopyrrolooxazepines and Pyrrolo-
benzoxazepines 92 
4.10 Conclusions and Future Directions 94 
5 Radioiodination and In Vivo Studies 95 
5.1 Radioiodination Methods 95 
5.2 Synthesis of 123I Compounds 97 
5.2.1 Synthesis of [123I]N,N-Diethyl-(5-chloro-2-(4-iodophenyl)indol-3-
yl)glyoxylamide 97 
5.2.2 Synthesis of [123I]N,N-Diethyl-[2-(4-iodophenyl)-5,7-dimethyl-
pyrazolo[1,5-a]pyrimidin-3-yl]acetamide 101 
5.3 In Vivo Biodistribution Studies 104 
5.3.1 In Vivo Biodistribution of [123I]N,N-Diethyl-(5-chloro-2-(4-
iodophenyl)indol-3-yl)glyoxylamide [142] 104 
5.3.2 In Vivo Biodistribution of [123I]N,N-Diethyl-[2-(4-iodophenyl)-5,7-
dimethylpyrazolo[1,5-a]pyrimidin-3-yl]acetamide [144] 107 
5.4 In Vivo Competition Studies 109 
5.4.1 In Vivo Competition Study of [123I]N,N-Diethyl-(5-chloro-2-(4-
iodophenyl)indol-3-yl)glyoxylamide [142] 109 
5.4.2 Competition Study of [123I]N,N-Diethyl-[2-(4-iodophenyl)-5,7-
dimethylpyrazolo[1,5-a]pyrimidin-3-yl]acetamide [144] 112 
5.5 In Vivo Stability Studies 114 
5.5.1 In Vivo Stability Study of [123I]N,N-Diethyl-(5-chloro-2-(4-
iodophenyl)indol-3-yl)glyoxylamide [142] 114 
 xv
5.5.2 In Vivo Stability Study of [123I]N,N-Diethyl-[2-(4-iodophenyl)-5,7-
dimethylpyrazolo[1,5-a]pyrimidin-3-yl]acetamide [144] 115 
5.6 Conclusion and Future Directions 117 
6 Conclusions and Future Directions 118 
7 Experimental 121 
7.1 General Experimental 121 
7.2 Experimental Procedures for the Synthesis of Indole Compounds 123 
7.2.1 Experimental Procedures for the Synthesis of 5-Chlorosubstituted 
Indol-3-ylglyoxylamides 123 
7.2.2 Experimental Procedures for the Synthesis of Indol-3-
ylglyoxylamides 133 
7.2.3 Experimental Procedures for the Synthesis of meta-Substituted 
Phenylindol-3-ylglyoxylamides 141 
7.2.4 Experimental Procedures for the Synthesis of Fluorinated Indol-3-
ylglyoxylamides 146 
7.3 Experimental Procedures for the Synthesis of 2-Arylpyrazolo[1,5-
a]pyrimidin-3-yl Acetamides 148 
7.4 Experimental Procedure for the Synthesis of Pyrrolobenzoxazepine and 
pyridopyrrolooxazepine compounds 159 
7.4.1 Synthesis of Ethyl (±)-α-bromophenylacetates 159 
7.4.2 Experimental Procedures for the Synthesis of Pyridopyrrolo-
oxazepines 162 
7.4.3 Experimental Procedures for the Synthesis of 
Pyrrolobenzoxazepines 170 
 xvi
7.5 Experimental Procedures for the Stannylation Reactions and 
Radioiodination Reactions 179 
7.6 Pharmacology Methods 182 
7.6.1 In Vitro Binding Assays for Peripheral Benzodiazepine Receptors 182 
7.6.2 In Vitro Binding Assays for Central Benzodiazepine Receptors 183 
7.6.3 In Vivo Biodistribution Studies for [123I]PBR200 [142] and 
[123I]PBR215 [144] 185 
7.6.4 In Vivo Competition Studies for [123I]PBR200 [142] and 
[123I]PBR215 [144] 186 
7.6.5 In Vivo Stability Studies for [123I]PBR200 [142] and [123I]PBR215 
[144]  187 
7.7 Lipophilicity Estimations 188 











List of Figures 
 
Figure 1.1  A schematic diagram of the structure of the PBR complex in the 
mitochondria. 3 
Figure 1.2  Possible endogenous PBR ligands. 6 
Figure 1.3  Synthetic PBR ligands. 8 
Figure 1.4  The mechanism of steroid and bile acid biosynthesis in the 
mitochondria of steroid producing cells and hepatic cells 
respectively. 10 
Figure 1.5  Hypothetical model for cholesterol transport into mitochondria. 12 
Figure 1.6  Structure of Ro5-4864 [6] and diazepam [11]. 17 
Figure 1.7 Imidazo[1,2-a]pyridine-3-acetamides [12], alpidem [7] and zolpidem 
[13]. 19 
Figure 1.8  General structure of imidazo[1,2-a]pyridine-3-acetamides [14]-[16]. 20 
Figure 1.9  General structure of 2-arylpyrazolo[1,5-a]pyrimidin-3-yl acetamides 
[17]. 20 
Figure 1.10  Potent PBR ligands: pyrrolobenzothiazepines [18], 
pyrrolobenzoxazepines [19], and pyridopyrrolooxazepines [20]. 21 
Figure 1.11 Opening of the diazepine ring of Ro5-4864 leading to new PBR 
ligands based on aryloxyanilide derivatives [21]. 22 
Figure 1.12  Structures of DAA1106 [22] and DAA1097 [23]. 23 
Figure 1.13 The basic structure of 2-aryl-3-indoleacetamides (FGIN-1) [24], and 
FGIN-1-44 [25]. 24 
 xviii
Figure 1.14  General structure of 3-aryl-3-pyrrol-1-ylpropanamides, analogues of 
FGIN-1 [24]. 24 
Figure 1.15  Structure of N,N-dialkyl-2-phenylindol-3-ylglyoxyamides [27]. 25 
Figure 1.16  PET detector and brain images obtained with a SPECT camera. 29 
Figure 1.17  DAA1106 radiolabelled with 18F. 31 
Figure 1.18  [11C]PK11195 [31] and PK11195 derivative, [11C]VC195 [30]. 31 
Figure 1.19  Carbon-11 radiolabelled pyrazolopyrimidine, [11C]DPA-713 [32]. 32 
Figure 1.20  123I radiolabelled PBR ligands. 33 
Figure 1.21  Proposed compound classes for synthesis and investigation. 35 
Figure 2.1  Structure of N,N-dialkyl-2-phenylindol-3-ylglyoxylamides. 36 
Figure 2.2  Structures and PBR binding affinities for several N,N-dialkyl-2-
phenylindol-3-ylglyoxylamides. 37 
Figure 2.3  Possible variations for the target indol-3-ylglyoxylamides. 38 
Figure 2.4  Iodinated target compound with the iodine on the alkyl chain. 38 
Figure 2.5  1H and 13C NMR spectra similarities in the indole moiety for indol-
3-ylglyoxylamides [48]-[54]. 45 
Figure 2.6  1H and 13C NMR spectra similarities in the indole moiety for indol-
3-ylglyoxylamides [63]-[67]. 49 
Figure 2.7  A fitted sigmoid curve showing the PBR IC50 of [65]. 54 
Figure 3.1  Basic structure of alpidem [7] and 2-arylpyrazolo[1,5-a]pyrimidin-3-
yl acetamide derivatives [17]. 61 
Figure 3.2  Structure of 2-phenylpyrazolo[1,5-a]pyrimidinyl-3-yl acetamides. 62 
Figure 3.3  Target iodinated 2-arylpyrazolo[1,5-a]pyrimidin-3-yl acetamides. 66 
Figure 3.4  1H NMR spectra assignments of butanamide [95], typical of 
butanamides [96]-[98]. 69 
 xix
Figure 3.5  1H NMR assignment of [91], typical of target compounds [90]-[92]. 72 
Figure 3.6  PBR and CBR binding affinities of [90]-[92]. 74 
Figure 4.1  General structure of pyrrolobenzothiazepines for the PBR. 77 
Figure 4.2  Selected pyridopyrrolooxazepines and pyrrolobenzoxazepines and 
their binding affinities (Ki) for PBR. 78 
Figure 4.3  Compound showing possible positions for radiolabelling with 123I. 79 
Figure 4.4  Proposed mechanism of radical reaction to form pyrido[3,2-
b]pyrrolo[1,2-d][1,4]oxazine-6-one [122]. 85 
Figure 4.5  PBR and CBR IC50 values for compounds [121], [123], [128], [130]. 93 
Figure 5.1  Radioiodination via nucleophilic addition to synthesise 
radioiodinated PK11195. 95 
Figure 5.2  Direct radioiodination (radioiodo-deprotonation) of tyrosine. 96 
Figure 5.3  Electrophilic radioiodination of a tributylstannyl group. 96 
Figure 5.4  Structure of two oxidants, chloramine-T and iodogen. 97 
Figure 5.5  Purification of [123I]PBR200 using a semipreparative RP HPLC 
column. 99 
Figure 5.6  Coinjection of iodo standard [50] with [123I]PBR200 [142] onto 
HPLC. 100 
Figure 5.7  HPLC purification of [123I]PBR200 when using chloramine-T. 100 
Figure 5.8  HPLC purification [123I]PBR215 when used chloramine-T. 103 
Figure 5.9  Purification of [123I]PBR215 (at 12 min) using a semipreparative RP 
HPLC column. 104 
Figure 5.10  Biodistribution of [123I]PBR200 in male Sprague-Dawley rats. 105 
Figure 5.11  Biodistribution of [123I]PBR200 in Sprague-Dawley rats in blood, 
brain, olfactory bulbs and testes. 106 
 xx 
Figure 5.12 Biodistribution of [123I]PBR215 in male Sprague-Dawley rats. 108 
Figure 5.13 Biodistribution of [123I]PBR215 in blood, brain, olfactory bulbs and 
testes. 109 
Figure 5.14 Effects of various drugs on [123I]PBR200 uptake in rat organs. 110 
Figure 5.15 Effects of various drugs on [123I]PBR200 uptake in rat blood, brain 
and olfactory bulbs. 111 
Figure 5.16 Effects of various drugs on [123I]PBR215 uptake in rat organs. 113 
Figure 5.17 Effects of various drugs on [123I]PBR215 uptake in rat organs. 113 


















List of Schemes 
 
Scheme 2.1  General synthesis of N,N-dialkyl-2-phenylindol-3-ylglyoxylamides. 39 
Scheme 2.2  Synthesis of [5-chloro-2-(4-halophenyl)indol-3-yl]glyoxylyl 
chlorides [46] and [47]. 41 
Scheme 2.3  Amination of [5-chloro-2-(4-iodophenyl)indol-3-yl]glyoxylyl 
chloride [46]. 42 
Scheme 2.4  Amination of [5-chloro-2-(4-bromophenyl)indol-3-yl]glyoxylyl 
chloride [47]. 44 
Scheme 2.5  Synthesis of non-chlorinated glyoxylyl chlorides. 46 
Scheme 2.6  Synthesis of 2-(4-bromophenyl)indole [60] via the Fischer indole 
synthesis. 47 
Scheme 2.7  Amination of [2-(4-halophenyl)indol-3-yl]glyoxylyl chlorides [61]-
[62]. 48 
Scheme 2.8  Synthesis of N,N-diethyl-[5-chloro-2-(3-iodophenyl)indol-3-
yl]glyoxylamide [73]. 50 
Scheme 2.9  Proposed synthetic scheme for the synthesis of N-((E)-3-iodoallyl-N-
methyl-2-(4-fluorophenyl)indol-3-ylglyoxylamide [41]. 53 
Scheme 3.1  General synthetic scheme for synthesis of 2-arylpyrazolo[1,5-
a]pyrimidin-3-ylacetamides. 65 
Scheme 3.2  Synthesis of key intermediate 4-iodobenzoylacetonitrile [89]. 67 
Scheme 3.3  Synthesis of butanamides [95]-[98]. 68 
Scheme 3.4  Mechanism for the synthesis of dialkylated product [99]. 70 
Scheme 3.5  Reaction of [96] with hydrazine hydrate in ethanol. 71 
 xxii
Scheme 3.6  Synthesis of pyrazoles [100]-[102]. 71 
Scheme 3.7  Synthesis of 2-arylpyrazolo[1,5-a]pyrimidin-3-yl acetamides [90]-
[92]. 72 
Scheme 4.1  General synthetic scheme for pyrrolobenzoxazepines and 
pyridopyrrolooxazepines. 80 
Scheme 4.2  Synthesis of ethyl (±)-α-bromophenylacetates [112] and [113]. 81 
Scheme 4.3  General synthesis of 7-[(diethylcarbamoyl)oxy]-6-(4-
iodophenyl)pyrido-[3,2-b]pyrrolo[1,2-d][1,4]oxazepine [121]. 83 
Scheme 4.4  An unexpected side-product from an O-alkylation reaction. 84 
Scheme 4.5  Carbon alkylation of [120] when using DMF as solvent. 86 
Scheme 4.6  Complete synthesis of target pyrrolobenzoxazepines [128] and [130]. 88 
Scheme 4.7  Carbon alkylation of [127] using DMF as solvent. 90 
Scheme 4.8  Attempted synthesis of 7-[(diethylcarbamoyl)oxy]-4-iodo-6-phenyl-
pyrrolo[2,1-d][1,5]benzoxazepine [138]. 91 
Scheme 5.1  Synthesis of [123I]N,N-diethyl-(5-chloro-2-(4-iodophenyl)indol-3-
yl)glyoxylamide [142]. 98 
Scheme 5.2  Synthesis of [123I]N,N-diethyl-[2-(4-iodophenyl)-5,7-








List of Tables 
 
Table 1.1 Difference between PBR and CBR. 2 
Table 1.2 Radionuclides and their uses. 28 
Table 2.1 Reaction and purification conditions and yields for compounds [48]-[51]. 42 
Table 2.2 1H and 13C NMR alkyl chain peak assignments for compounds [48]-[51]. 43 
Table 2.3 Reaction and purification conditions and yields for compounds [52]-[54]. 44 
Table 2.4 Reaction and purification conditions and yields for compounds [63]-[67]. 48 
Table 2.5 PBR and CBR binding affinities (IC50) of halogenated indolglyoxylamides. 55 
Table 2.6 PBR Ki values of similar new indolylgloxylamides. 59 
Table 3.1 PBR binding affinities of selected 2-arylpyrazolo[1,5-a]pyrimidinyl-3-yl 
acetamides. 63 
